Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes.

Wagner S, Roberson D, Boland J, Kreimer AR, Yeager M, Cullen M, Mirabello L, Dunn ST, Walker J, Zuna R, Porras C, Cortes B, Sampson J, Herrero R, Rodriguez AC, Quint W, Van Doorn LJ; CVT Group , Hildesheim A, Schiffman M, Wentzensen N.

J Infect Dis. 2019 Oct 8;220(10):1609-1619. doi: 10.1093/infdis/jiz324.

2.

Impact of Host DNA and Sequencing Depth on the Taxonomic Resolution of Whole Metagenome Sequencing for Microbiome Analysis.

Pereira-Marques J, Hout A, Ferreira RM, Weber M, Pinto-Ribeiro I, van Doorn LJ, Knetsch CW, Figueiredo C.

Front Microbiol. 2019 Jun 12;10:1277. doi: 10.3389/fmicb.2019.01277. eCollection 2019.

3.

Efficacy and Toxicity of Weekly Carboplatin and Paclitaxel as Induction or Palliative Treatment in Advanced Esophageal Cancer Patients.

de Man FM, van Eerden RAG, Oomen-de Hoop E, Veraart JN, van Doorn N, van Doorn L, van der Gaast A, Mathijssen RHJ.

Cancers (Basel). 2019 Jun 13;11(6). pii: E826. doi: 10.3390/cancers11060826.

4.

Using maximal systolic acceleration to diagnose and assess the severity of peripheral artery disease in a flow model study.

Brouwers JJWM, van Doorn LP, van Wissen RC, Putter H, Hamming JF.

J Vasc Surg. 2019 May 27. pii: S0741-5214(19)30400-8. doi: 10.1016/j.jvs.2019.01.088. [Epub ahead of print]

PMID:
31147131
5.

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.

Buisman FE, Homs MYV, Grünhagen DJ, Filipe WF, Bennink RJ, Besselink MGH, Borel Rinkes IHM, Bruijnen RCG, Cercek A, D'Angelica MI, van Delden OM, Donswijk ML, van Doorn L, Doornebosch PG, Emmering J, Erdmann JI, IJzerman NS, Grootscholten C, Hagendoorn J, Kemeny NE, Kingham TP, Klompenhouwer EG, Kok NFM, Koolen S, Kuhlmann KFD, Kuiper MC, Lam MGE, Mathijssen RHJ, Moelker A, Oomen-de Hoop E, Punt CJA, Te Riele WW, Roodhart JML, Swijnenburg RJ, Prevoo W, Tanis PJ, Vermaas M, Versleijen MWJ, Veuger FP, Weterman MJ, Verhoef C, Groot Koerkamp B.

BMC Cancer. 2019 Apr 5;19(1):327. doi: 10.1186/s12885-019-5515-6.

6.

Comparison of Amsel criteria, Nugent score, culture and two CE-IVD marked quantitative real-time PCRs with microbiota analysis for the diagnosis of bacterial vaginosis.

van den Munckhof EHA, van Sitter RL, Boers KE, Lamont RF, Te Witt R, le Cessie S, Knetsch CW, van Doorn LJ, Quint WGV, Molijn A, Leverstein-van Hall MA.

Eur J Clin Microbiol Infect Dis. 2019 May;38(5):959-966. doi: 10.1007/s10096-019-03538-7. Epub 2019 Mar 22.

PMID:
30903536
7.

Evaluation of a stepwise approach using microbiota analysis, species-specific qPCRs and culture for the diagnosis of lower respiratory tract infections.

van den Munckhof EHA, de Koning MNC, Quint WGV, van Doorn LJ, Leverstein-van Hall MA.

Eur J Clin Microbiol Infect Dis. 2019 Apr;38(4):747-754. doi: 10.1007/s10096-019-03511-4. Epub 2019 Feb 20.

PMID:
30788730
8.

Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy.

Versmissen J, van Doorn L, Mirabito Colafella KM, Mathijssen RH, Danser AHJ.

J Hypertens. 2018 Nov;36(11):2279-2280. doi: 10.1097/HJH.0000000000001894. No abstract available.

PMID:
30256328
9.

High Rate of Infection by Only Oncogenic Human Papillomavirus in Amerindians.

Vargas-Robles D, Magris M, Morales N, de Koning MNC, Rodríguez I, Nieves T, Godoy-Vitorino F, Sánchez GI, Alcaraz LD, Forney LJ, Pérez ME, García-Briceño L, van Doorn LJ, Domínguez-Bello MG.

mSphere. 2018 May 2;3(3). pii: e00176-18. doi: 10.1128/mSphere.00176-18. eCollection 2018 May-Jun.

10.

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial.

Safaeian M, Sampson JN, Pan Y, Porras C, Kemp TJ, Herrero R, Quint W, van Doorn LJ, Schussler J, Lowy DR, Schiller J, Schiffman MT, Rodriguez AC, Gail MH, Hildesheim A, Gonzalez P, Pinto LA, Kreimer AR; Costa Rica HPV Vaccine Trial (CVT) Group.

J Natl Cancer Inst. 2018 Feb 1;110(2). doi: 10.1093/jnci/djx158.

11.

Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.

Beukhof CM, van Doorn L, Visser TJ, Bins S, Visser WE, van Heerebeek R, van Kemenade FJ, de Rijke YB, de Herder WW, Chaker L, Mathijssen RH, Peeters RP.

J Clin Endocrinol Metab. 2017 Aug 1;102(8):2922-2929. doi: 10.1210/jc.2016-4025.

PMID:
28575418
12.

Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.

Bins S, van Doorn L, Phelps MA, Gibson AA, Hu S, Li L, Vasilyeva A, Du G, Hamberg P, Eskens F, de Bruijn P, Sparreboom A, Mathijssen R, Baker SD.

Clin Transl Sci. 2017 Jul;10(4):271-279. doi: 10.1111/cts.12458. Epub 2017 Mar 31.

13.

Capecitabine and the Risk of Fingerprint Loss.

van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R.

JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. No abstract available.

PMID:
27560202
14.

Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.

Bins S, Lenting A, El Bouazzaoui S, van Doorn L, Oomen-de Hoop E, Eskens FA, van Schaik RH, Mathijssen RH.

Pharmacogenomics. 2016 Sep;17(14):1483-90. doi: 10.2217/pgs-2016-0063. Epub 2016 Aug 17.

PMID:
27533851
15.

Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients.

Verheijen RB, Bins S, Mathijssen RH, Lolkema MP, van Doorn L, Schellens JH, Beijnen JH, Langenberg MH, Huitema AD, Steeghs N; Dutch Pharmacology Oncology Group.

Clin Cancer Res. 2016 Dec 1;22(23):5738-5746. Epub 2016 Jul 28.

16.

Correction for Geraets et al., Clinical Evaluation of a GP5+/6+-Based Luminex Assay Having Full High-Risk Human Papillomavirus Genotyping Capability and an Internal Control.

Geraets DT, Cuschieri K, de Koning MNC, van Doorn LJ, Snijders PJF, Meijer CJLM, Quint WGV, Arbyn M.

J Clin Microbiol. 2016 Jul;54(7):1927. doi: 10.1128/JCM.00753-16. No abstract available.

17.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.

Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, Kleter B, van Doorn LJ, Chaturvedi AK, Hildesheim A, Schiffman M, Wang SS, Zuna RE, Walker JL, Dunn ST, Wentzensen N.

BMC Infect Dis. 2015 Nov 25;15:544. doi: 10.1186/s12879-015-1281-5.

18.

Increased Aggregation Is More Frequently Associated to Human Disease-Associated Mutations Than to Neutral Polymorphisms.

De Baets G, Van Doorn L, Rousseau F, Schymkowitz J.

PLoS Comput Biol. 2015 Sep 4;11(9):e1004374. doi: 10.1371/journal.pcbi.1004374. eCollection 2015 Sep.

19.

The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation.

Lolkema MP, Bohets HH, Arkenau HT, Lampo A, Barale E, de Jonge MJA, van Doorn L, Hellemans P, de Bono JS, Eskens FALM.

Clin Cancer Res. 2015 May 15;21(10):2297-2304. doi: 10.1158/1078-0432.CCR-14-3258. Epub 2015 Mar 5.

20.

Gastroenteritis attributable to rotavirus in hospitalized Saudi Arabian children in the period 2007-2008.

Khalil M, Azhar E, Kao M, Al-Kaiedi N, Alhani H, Al Olayan I, Pawinski R, Gopala K, Kandeil W, Anis S, Van Doorn LJ, DeAntonio R.

Clin Epidemiol. 2015 Feb 11;7:129-37. doi: 10.2147/CLEP.S69502. eCollection 2015.

21.

The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra.

Geraets DT, Struijk L, Kleter B, Molijn A, van Doorn LJ, Quint WG, Colau B.

J Virol Methods. 2015 Apr;215-216:22-9. doi: 10.1016/j.jviromet.2015.01.001. Epub 2015 Feb 16.

PMID:
25698462
22.

Phase I study of cisplatin, hyperthermia, and lapatinib in patients with recurrent carcinoma of the uterine cervix in a previously irradiated area.

van Meerten E, Franckena M, Wiemer E, van Doorn L, Kraan J, Westermann A, Sleijfer S.

Oncologist. 2015 Mar;20(3):241-2. doi: 10.1634/theoncologist.2014-0365. Epub 2015 Feb 6.

23.

A phase Ib study of the VEGF receptor tyrosine kinase inhibitor tivozanib and modified FOLFOX-6 in patients with advanced gastrointestinal malignancies.

Oldenhuis CN, Loos WJ, Esteves B, van Doorn L, Cotreau MM, Strahs AL, den Hollander MW, Gietema JA, de Vries EG, Eskens FA.

Clin Colorectal Cancer. 2015 Mar;14(1):18-24.e1. doi: 10.1016/j.clcc.2014.12.001. Epub 2014 Dec 16.

PMID:
25591799
24.

Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex type-specific PCR assay for HPV DNA.

Struyf F, Colau B, Wheeler CM, Naud P, Garland S, Quint W, Chow SN, Salmerón J, Lehtinen M, Del Rosario-Raymundo MR, Paavonen J, Teixeira JC, Germar MJ, Peters K, Skinner SR, Limson G, Castellsagué X, Poppe WA, Ramjattan B, Klein TD, Schwarz TF, Chatterjee A, Tjalma WA, Diaz-Mitoma F, Lewis DJ, Harper DM, Molijn A, van Doorn LJ, David MP, Dubin G; HPV PATRICIA Study Group.

Clin Vaccine Immunol. 2015 Feb;22(2):235-44. doi: 10.1128/CVI.00457-14. Epub 2014 Dec 24.

25.

TEMPORARY REMOVAL: The original SPF10 LiPA25 algorithm is more sensitive and suitable for epidemiologic HPV research than the SPF10 INNO-LiPA Extra.

Geraets DT, Struijk L, Kleter B, Molijn A, van Doorn L, Quint WG, Colau B.

J Virol Methods. 2014 Dec 2;213C:1. doi: 10.1016/j.jviromet.2014.11.008. [Epub ahead of print]

PMID:
25476446
26.

Burden and genotyping of rotavirus disease in the United Arab Emirates: a multicenter hospital-based surveillance.

Howidi M, Balhaj G, Yaseen H, Gopala K, Van Doorn LJ, DeAntonio R.

Hum Vaccin Immunother. 2014;10(8):2284-9. doi: 10.4161/hv.29386.

27.

In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.

Ottosen S, Parsley TB, Yang L, Zeh K, van Doorn LJ, van der Veer E, Raney AK, Hodges MR, Patick AK.

Antimicrob Agents Chemother. 2015 Jan;59(1):599-608. doi: 10.1128/AAC.04220-14. Epub 2014 Nov 10.

28.

Sexual rehabilitation after pelvic radiotherapy and vaginal dilator use: consensus using the Delphi method.

Bakker RM, ter Kuile MM, Vermeer WM, Nout RA, Mens JW, van Doorn LC, de Kroon CD, Hompus WC, Braat C, Creutzberg CL.

Int J Gynecol Cancer. 2014 Oct;24(8):1499-506. doi: 10.1097/IGC.0000000000000253.

PMID:
25248115
29.

Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.

Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M.

J Clin Microbiol. 2014 Nov;52(11):3996-4002. doi: 10.1128/JCM.01962-14. Epub 2014 Sep 10. Erratum in: J Clin Microbiol. 2016 Jul;54(7):1927.

30.

Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.

Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M; Costa Rica Vaccine Trial Group.

Am J Epidemiol. 2014 Sep 15;180(6):599-607. doi: 10.1093/aje/kwu168. Epub 2014 Aug 19.

31.

Reduced prevalence of vulvar HPV16/18 infection among women who received the HPV16/18 bivalent vaccine: a nested analysis within the Costa Rica Vaccine Trial.

Lang Kuhs KA, Gonzalez P, Rodriguez AC, van Doorn LJ, Schiffman M, Struijk L, Chen S, Quint W, Lowy DR, Porras C, DelVecchio C, Jimenez S, Safaeian M, Schiller JT, Wacholder S, Herrero R, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2014 Dec 15;210(12):1890-9. doi: 10.1093/infdis/jiu357. Epub 2014 Jun 23.

32.

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours.

Eskens FA, Tresca P, Tosi D, Van Doorn L, Fontaine H, Van der Gaast A, Veyrat-Follet C, Oprea C, Hospitel M, Dieras V.

Br J Cancer. 2014 Apr 29;110(9):2170-7. doi: 10.1038/bjc.2014.137. Epub 2014 Apr 8.

33.

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus.

Robbins HA, Li Y, Porras C, Pawlita M, Ghosh A, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Gonzalez P, Schiller J, Lowy D, Esser M, Matys K, Quint W, van Doorn LJ, Herrero R, Pinto LA, Hildesheim A, Waterboer T, Safaeian M.

BMC Infect Dis. 2014 Mar 3;14:120. doi: 10.1186/1471-2334-14-120.

34.

Manufacturer changes lead to clinically important differences between two editions of the TNO stereotest.

van Doorn LL, Evans BJ, Edgar DF, Fortuin MF.

Ophthalmic Physiol Opt. 2014 Mar;34(2):243-9. doi: 10.1111/opo.12101. Epub 2013 Dec 19.

PMID:
24355036
35.

Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections.

Geraets DT, van Doorn LJ, Kleter B, Colau B, Harper DM, Quint WG.

PLoS One. 2013 Nov 11;8(11):e80382. doi: 10.1371/journal.pone.0080382. eCollection 2013.

36.

Racial disparities in Human Papillomavirus (HPV) associated head and neck cancer.

Jiron J, Sethi S, Ali-Fehmi R, Franceschi S, Struijk L, van Doorn LJ, Quint W, Kato I.

Am J Otolaryngol. 2014 Mar-Apr;35(2):147-53. doi: 10.1016/j.amjoto.2013.09.004. Epub 2013 Sep 28.

37.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

38.

Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica.

Lang Kuhs KA, Gonzalez P, Struijk L, Castro F, Hildesheim A, van Doorn LJ, Rodriguez AC, Schiffman M, Quint W, Lowy DR, Porras C, Delvecchio C, Katki HA, Jimenez S, Safaeian M, Schiller J, Solomon D, Wacholder S, Herrero R, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2013 Nov 15;208(10):1643-52. doi: 10.1093/infdis/jit369. Epub 2013 Sep 6.

39.

Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.

Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group.

PLoS One. 2013 Jul 17;8(7):e68329. doi: 10.1371/journal.pone.0068329. Print 2013.

40.

Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance.

Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A.

Clin Pharmacol Ther. 2013 Nov;94(5):585-92. doi: 10.1038/clpt.2013.145. Epub 2013 Jul 17.

41.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

42.

A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay.

van Alewijk D, Kleter B, Vent M, Delroisse JM, de Koning M, van Doorn LJ, Quint W, Colau B.

J Clin Microbiol. 2013 Apr;51(4):1171-8. doi: 10.1128/JCM.02831-12. Epub 2013 Jan 30.

43.

HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays.

Lin SW, Ghosh A, Porras C, Markt SC, Rodriguez AC, Schiffman M, Wacholder S, Kemp TJ, Pinto LA, Gonzalez P, Wentzensen N, Esser MT, Matys K, Meuree A, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Safaeian M; Costa Rican Vaccine Trial Group.

PLoS One. 2013;8(1):e53067. doi: 10.1371/journal.pone.0053067. Epub 2013 Jan 2.

44.

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.

Vencken PM, Kriege M, Hooning M, Menke-Pluymers MB, Heemskerk-Gerritsen BA, van Doorn LC, Collée MM, Jager A, van Montfort C, Burger CW, Seynaeve C.

Cancer. 2013 Mar 1;119(5):955-62. doi: 10.1002/cncr.27839. Epub 2012 Nov 16.

45.

Oral live attenuated human rotavirus vaccine (Rotarix™) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.

Justino MC, Araújo EC, van Doorn LJ, Oliveira CS, Gabbay YB, Mascarenhas JD, Miranda YS, Guerra Sde F, Silva VB, Linhares AC.

Mem Inst Oswaldo Cruz. 2012 Nov;107(7):846-53.

46.

Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial.

Steele AD, Neuzil KM, Cunliffe NA, Madhi SA, Bos P, Ngwira B, Witte D, Todd S, Louw C, Kirsten M, Aspinall S, Van Doorn LJ, Bouckenooghe A, Suryakiran PV, Han HH.

BMC Infect Dis. 2012 Sep 13;12:213. doi: 10.1186/1471-2334-12-213.

47.

Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica.

Castro FA, Quint W, Gonzalez P, Katki HA, Herrero R, van Doorn LJ, Schiffman M, Struijk L, Rodriguez AC, DelVecchio C, Lowy DR, Porras C, Jimenez S, Schiller J, Solomon D, Wacholder S, Hildesheim A, Kreimer AR; Costa Rica Vaccine Trial Group.

J Infect Dis. 2012 Oct 1;206(7):1103-10. Epub 2012 Jul 30.

48.

Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials.

Safaeian M, Ghosh A, Porras C, Lin SW, Rodriguez AC, Schiffman M, Wacholder S, Kemp T, Gonzalez P, Wentzensen N, Esser M, Meuree A, Matys K, Quint W, van Doorn LJ, Sherman ME, Herrero R, Pinto LA, Hildesheim A.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1547-54. doi: 10.1158/1055-9965.EPI-12-0558. Epub 2012 Jul 2.

49.

Influence of smoking on the pharmacokinetics and toxicity profiles of taxane therapy.

de Graan AJ, Loos WJ, Friberg LE, Baker SD, van der Bol JM, van Doorn L, Wiemer EA, van der Holt B, Verweij J, Mathijssen RH.

Clin Cancer Res. 2012 Aug 15;18(16):4425-32. doi: 10.1158/1078-0432.CCR-12-0728. Epub 2012 May 29.

50.

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors.

Banerji U, van Doorn L, Papadatos-Pastos D, Kristeleit R, Debnam P, Tall M, Stewart A, Raynaud F, Garrett MD, Toal M, Hooftman L, De Bono JS, Verweij J, Eskens FA.

Clin Cancer Res. 2012 May 1;18(9):2687-94. doi: 10.1158/1078-0432.CCR-11-3165.

Supplemental Content

Loading ...
Support Center